Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions.

Murza A, Sainsily X, Coquerel D, Côté J, Marx P, Besserer-Offroy É, Longpré JM, Lainé J, Reversade B, Salvail D, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É.

J Med Chem. 2016 Apr 14;59(7):2962-72. doi: 10.1021/acs.jmedchem.5b01549. Epub 2016 Mar 30.

PMID:
26986036
2.

Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension.

Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ, Davenport AP.

Circulation. 2017 Mar 21;135(12):1160-1173. doi: 10.1161/CIRCULATIONAHA.116.023218. Epub 2017 Jan 30.

3.

ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.

Sato T, Sato C, Kadowaki A, Watanabe H, Ho L, Ishida J, Yamaguchi T, Kimura A, Fukamizu A, Penninger JM, Reversade B, Ito H, Imai Y, Kuba K.

Cardiovasc Res. 2017 Jun 1;113(7):760-769. doi: 10.1093/cvr/cvx061.

PMID:
28371822
4.

Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.

Yang P, Maguire JJ, Davenport AP.

Trends Pharmacol Sci. 2015 Sep;36(9):560-7. doi: 10.1016/j.tips.2015.06.002. Epub 2015 Jul 1. Review.

5.

Elabela-apelin receptor signaling pathway is functional in mammalian systems.

Wang Z, Yu D, Wang M, Wang Q, Kouznetsova J, Yang R, Qian K, Wu W, Shuldiner A, Sztalryd C, Zou M, Zheng W, Gong DW.

Sci Rep. 2015 Feb 2;5:8170. doi: 10.1038/srep08170.

6.

ELABELA: a hormone essential for heart development signals via the apelin receptor.

Chng SC, Ho L, Tian J, Reversade B.

Dev Cell. 2013 Dec 23;27(6):672-80. doi: 10.1016/j.devcel.2013.11.002. Epub 2013 Dec 5.

7.

ELABELA: a novel hormone in cardiac development acting as a new endogenous ligand for the APJ receptor.

Xie F, Lv D, Chen L.

Acta Biochim Biophys Sin (Shanghai). 2014 Jul;46(7):620-2. doi: 10.1093/abbs/gmu032. Epub 2014 May 14. No abstract available.

PMID:
24829400
8.

ELABELA Improves Cardio-Renal Outcome in Fatal Experimental Septic Shock.

Coquerel D, Chagnon F, Sainsily X, Dumont L, Murza A, Côté J, Dumaine R, Sarret P, Marsault É, Salvail D, Auger-Messier M, Lesur O.

Crit Care Med. 2017 Nov;45(11):e1139-e1148. doi: 10.1097/CCM.0000000000002639.

PMID:
28777197
9.

Structure-activity relationship of novel macrocyclic biased apelin receptor agonists.

Murza A, Sainsily X, Côté J, Bruneau-Cossette L, Besserer-Offroy É, Longpré JM, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É.

Org Biomol Chem. 2017 Jan 4;15(2):449-458. doi: 10.1039/c6ob02247b.

PMID:
27924341
10.

[Functional dissociation between apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure].

Iturrioz X, El Messari S, De Mota N, Fassot C, Alvear-Perez R, Maigret B, Llorens-Cortes C.

Arch Mal Coeur Vaiss. 2007 Aug;100(8):704-8. French.

PMID:
17928781
11.

The hypotensive effect of activated apelin receptor is correlated with β-arrestin recruitment.

Besserer-Offroy É, Bérubé P, Côté J, Murza A, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Marsault É, Sarret P.

Pharmacol Res. 2018 May;131:7-16. doi: 10.1016/j.phrs.2018.02.032. Epub 2018 Mar 9.

PMID:
29530600
12.

ELABELA Is an Endogenous Growth Factor that Sustains hESC Self-Renewal via the PI3K/AKT Pathway.

Ho L, Tan SY, Wee S, Wu Y, Tan SJ, Ramakrishna NB, Chng SC, Nama S, Szczerbinska I, Chan YS, Avery S, Tsuneyoshi N, Ng HH, Gunaratne J, Dunn NR, Reversade B.

Cell Stem Cell. 2015 Oct 1;17(4):435-47. doi: 10.1016/j.stem.2015.08.010. Epub 2015 Sep 17. Erratum in: Cell Stem Cell. 2015 Nov 5;17(5):635. Sczerbinska, Iwona [corrected to Szczerbinska, Iwona].

13.

Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression.

Atluri P, Morine KJ, Liao GP, Panlilio CM, Berry MF, Hsu VM, Hiesinger W, Cohen JE, Joseph Woo Y.

Cell Mol Biol Lett. 2007;12(1):127-38. Epub 2006 Nov 19.

14.

Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.

Kuba K, Sato T, Imai Y, Yamaguchi T.

Peptides. 2019 Jan;111:62-70. doi: 10.1016/j.peptides.2018.04.011. Epub 2018 Apr 21. Review.

PMID:
29684595
15.

Cardiac action of the first G protein biased small molecule apelin agonist.

Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC, Foster RE, Davenport AP.

Biochem Pharmacol. 2016 Sep 15;116:63-72. doi: 10.1016/j.bcp.2016.07.018. Epub 2016 Jul 27.

16.

Apela Regulates Fluid Homeostasis by Binding to the APJ Receptor to Activate Gi Signaling.

Deng C, Chen H, Yang N, Feng Y, Hsueh AJ.

J Biol Chem. 2015 Jul 24;290(30):18261-8. doi: 10.1074/jbc.M115.648238. Epub 2015 May 20.

17.

Sustained ELABELA Gene Therapy in High-salt Diet-induced Hypertensive Rats.

Schreiber CA, Holditch SJ, Generous A, Ikeda Y.

Curr Gene Ther. 2017;16(5):349-360. doi: 10.2174/1566523217666161121111906.

PMID:
27903222
18.

[The functional role of endogenous APJ agonists; Apelin and Elabela/Toddler in cardiovascular diseases].

Sato T, Kuba K.

Nihon Yakurigaku Zasshi. 2019;153(4):172-178. doi: 10.1254/fpj.153.172. Japanese.

PMID:
30971657
19.

The mechanosensitive APJ internalization via clathrin-mediated endocytosis: A new molecular mechanism of cardiac hypertrophy.

He L, Chen L, Li L.

Med Hypotheses. 2016 May;90:6-10. doi: 10.1016/j.mehy.2016.02.017. Epub 2016 Feb 27.

PMID:
27063076
20.

Apelin-36 Modulates Blood Glucose and Body Weight Independently of Canonical APJ Receptor Signaling.

Galon-Tilleman H, Yang H, Bednarek MA, Spurlock SM, Paavola KJ, Ko B, To C, Luo J, Tian H, Jermutus L, Grimsby J, Rondinone CM, Konkar A, Kaplan DD.

J Biol Chem. 2017 Feb 3;292(5):1925-1933. doi: 10.1074/jbc.M116.748103. Epub 2016 Dec 19.

Supplemental Content

Support Center